Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-23 8:19 pm Purchase | 2025-03-31 | 13G | Cardiff Oncology, Inc. CRDF | BlackRock Inc. BLK | 3,841,097 5.800% | 1,000,188 (+35.21%) | Filing History |
| 2025-02-12 2:48 pm Unchanged | 2024-12-31 | 13G | Cardiff Oncology, Inc. CRDF | PFIZER INC PFE | 2,411,575 3.600% | 0 (Unchanged) | Filing History |
| 2025-02-05 5:28 pm Purchase | 2024-12-31 | 13G | Cardiff Oncology, Inc. CRDF | BlackRock Inc. BLK | 2,840,909 4.300% | 105,328 (+3.85%) | Filing History |
| 2024-12-17 4:06 pm Purchase | 2024-12-10 | 13G | Cardiff Oncology, Inc. CRDF | Commodore Capital LP | 5,384,616 8.100% | 5,384,616 (New Position) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Cardiff Oncology, Inc. CRDF | BlackRock Inc. BLK | 2,735,581 5.900% | 0 (Unchanged) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Cardiff Oncology, Inc. CRDF | BlackRock Inc. BLK | 2,735,581 5.900% | 2,063,614 (+307.10%) | Filing History |
| 2024-02-06 4:01 pm Sale | 2023-12-31 | 13G | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 1,946,762 4.200% | -1,096,411 (-36.03%) | Filing History |
| 2023-02-14 12:47 pm Sale | 2022-12-31 | 13G | Cardiff Oncology, Inc. CRDF | CAXTON CORP | 983,607 2.200% | -2,495,733 (-71.73%) | Filing History |
| 2023-02-09 09:23 am Sale | 2022-12-31 | 13G | Cardiff Oncology, Inc. CRDF | JANUS HENDERSON GROUP PLC JHG | 0 0.000% | -3,523,012 (Position Closed) | Filing History |
| 2023-01-26 1:30 pm Unchanged | 2023-01-26 | 13G | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 3,043,173 6.380% | 0 (Unchanged) | Filing History |
| 2023-01-26 1:28 pm Sale | 2022-09-13 | 13D | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 3,043,173 6.380% | -2,947,666 (-49.20%) | Filing History |
| 2022-07-08 4:56 pm Sale | 2022-06-30 | 13G | Cardiff Oncology, Inc. CRDF | BlackRock Inc. BLK | 671,967 1.600% | -1,860,281 (-73.46%) | Filing History |
| 2022-02-14 4:13 pm Purchase | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | CAXTON CORP | 3,479,340 8.100% | 380,893 (+12.29%) | Filing History |
| 2022-02-14 4:04 pm Sale | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | Corriente Advisors LLC | 0 0.000% | -2,000,000 (Position Closed) | Filing History |
| 2022-02-11 7:12 pm Sale | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | Avidity Partners Management LP | 0 0.000% | -2,153,600 (Position Closed) | Filing History |
| 2022-02-10 2:25 pm Purchase | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | JANUS HENDERSON GROUP PLC JHG | 3,523,012 8.400% | 1,385,341 (+64.81%) | Filing History |
| 2022-02-09 12:06 pm Sale | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | STATE STREET CORP STT | 693,445 1.650% | -1,855,327 (-72.79%) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | BlackRock Inc. BLK | 2,532,248 6.000% | 2,532,248 (New Position) | Filing History |
| 2021-11-19 4:02 pm Purchase | 2021-11-18 | 13G | Cardiff Oncology, Inc. CRDF | PFIZER INC PFE | 2,411,575 5.750% | 2,411,575 (New Position) | Filing History |
| 2021-02-16 3:30 pm Purchase | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | CAXTON CORP | 3,098,447 8.800% | 1,140,204 (+58.23%) | Filing History |